Literature DB >> 3537221

Fast neutron therapy for malignant astrocytomas. A review.

P D Kurup, T F Pajak, J S Nelson, J Mansell, F R Hendrickson, L Cohen, T W Griffin.   

Abstract

The treatment of supratentorial malignant gliomas has continued to be a major problem for neurosurgeons and oncologists. Post-operative conventional radiotherapy is known to prolong survival and to enhance the quality of life. Local persistence of tumor kills the majority of patients. Fast neutron irradiation is being utilized to treat malignant gliomas based on its reputed radiobiological advantages for treatment of large tumors and the encouraging preliminary reports showing tumor eradication in post-radiation biopsy and autopsy specimens. This paper reviews the results of fast neutron irradiation alone and in combination with photons and hypoxic cell sensitizers. Survival comparisons do not show any superiority for neutrons compared to conventional radiation. However, post-neutron radiation tissue samples have shown less aggressive and minimal residual tumor in many instances. At the same time radiation necrosis has emerged as a significant problem. In summary, even though neutron irradiation can eradicate malignant gliomas a therapeutic window has yet to be identified.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537221     DOI: 10.1007/BF00165372

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Should we treat glioblastoma multiforme? A study of survival in 425 cases.

Authors:  J M TAVERAS; H G THOMPSON; J L POOL
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1962-03

2.  Fast neutron and mixed (neutron/photon) beam teletherapy for grades III and IV astrocytomas.

Authors:  G E Laramore; T W Griffin; A J Gerdes; R G Parker
Journal:  Cancer       Date:  1978-07       Impact factor: 6.860

3.  Treatment experience. Glioblastoma multiforme treated with 15 MeV fast neutrons.

Authors:  A Herskovic; R D Ornitz; M Shell; C C Rogers
Journal:  Cancer       Date:  1982-06-15       Impact factor: 6.860

4.  The response of Chinese hamster ovary cells to fast-neutron radiotherapy beams. II. Sublethal and potentially lethal damage recovery capabilities.

Authors:  R L Gragg; R M Humphrey; R E Meyn
Journal:  Radiat Res       Date:  1977-08       Impact factor: 2.841

5.  The Fermilab Neutron Therapy Facility: treatment planning for neutron and mixed beams.

Authors:  M Awschalom; I Rosenberg; R Ten Haken; L Cohen; F R Hendrickson
Journal:  Strahlentherapie Sonderb       Date:  1981

6.  Misonidazole and radiotherapy to treat malignant glioma: a phase II trial of the radiation therapy oncology group.

Authors:  S C Carabell; L A Bruno; A S Weinstein; M P Richter; C H Chang; C B Weiler; R L Goodman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-01       Impact factor: 7.038

7.  Patterns of failure in intracranial astrocytomas after irradiation: analysis of dose and field factors.

Authors:  O M Salazar; P Rubin; J V McDonald; M L Feldstein
Journal:  AJR Am J Roentgenol       Date:  1976-02       Impact factor: 3.959

8.  Fast neutron beam radiotherapy of glioblastoma multiforme.

Authors:  R G Parker; H C Berry; A J Gerdes; M D Soronen; C M Shaw
Journal:  AJR Am J Roentgenol       Date:  1976-08       Impact factor: 3.959

9.  A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.

Authors:  D F Nelson; D Schoenfeld; A S Weinstein; J S Nelson; T Wasserman; R L Goodman; S Carabell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-08       Impact factor: 7.038

10.  Misonidazole in radiotherapy of supratentorial malignant brain gliomas in adult patients: a randomized double-blind study.

Authors: 
Journal:  Eur J Cancer Clin Oncol       Date:  1983-01
View more
  1 in total

Review 1.  The rationale and requirements for the development of boron neutron capture therapy of brain tumors.

Authors:  A H Soloway; R F Barth; R A Gahbauer; T E Blue; J H Goodman
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.